Abstract
BackgroundEarly response to certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has been shown to predict long-term probability of low disease activity and inhibition of progression of structural joint damage in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have